Chugai Pharmaceutical
Headquarters country
Japan
Registry sponsor category
Industry
- Company name
- Chugai Pharmaceutical
- Organisation type
- Industry
- Registered legal name
- 中外製薬株式会社
- Registry sponsor category
- Industry
- Chugai Pharmaceutical Co.
- Chugai Pharmaceutical
- Chugai Pharmaceutical Co., Ltd. (Sponsor in Taiwan and Japan)
- Legal Entity Identifier (LEI)
- 529900T9LAII161DCN95
Related records
Trials (114)
- A Clinical Pharmacology Study to Evaluate the Effect of GYM329 on Disuse Muscle Atrophy in Healthy Volunteer
- A Clinical Study Investigating the Safety, Tolerability, PK and PD of PCO371 in Patients With Hypoparathyroidism
- A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
- A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
- A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors
- A Decentralized Home-Based Study To Investigate Novel Objective Biomarker Of Gluten-Mediated Symptoms In Celiac Disease Participants (CeDar ROSE Study)
- A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).
- A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).
- A Multiple-dose Study of Gantenerumab in Japanese Alzheimer's Disease Patients
- A New Active Vitamin D, ED-71 for Osteoporosis
- A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors
- A Phase 2 Study of CIM331 for Atopic Dermatitis Patients
- A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER
- A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma
- A Phase I Study of GC33 in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)
- A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
- A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer
- A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer
- A Phase1 Study to Explore the Safety of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis
- A Single Ascending Dose Study of PCO371 in Healthy Volunteers